Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
This article was originally published in The Pink Sheet Daily
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
You may also be interested in...
Generic drugs office will proactively seek litigation and other information that could affect launch timing.
FDA offers two-prong criteria to determine which ANDAs would get priority in review system; industry wants expanded classification that includes drug shortages.
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.